JPRN-UMIN000027167已完成未知
Availability of DR-1 on the assessment of tear film on the ocular surface - DR-1 on the assessment of tear film
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •patients undergone ophthalmic surgery within 6 months patients with lacrimal punctal plugs patients with severe systemic diseases
研究者
相似试验
进行中（未招募）
不适用
Durable response therapy evaluation for early or new onset type 1 diabetes mellitusOtelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are currently no approved treatments for this indication.Approved treatments for T1DM in the EU are insulins or insulin analogues.MedDRA version: 14.0Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-002205-40-FIGlaxoSmithKline240
进行中（未招募）
不适用
Durable response therapy evaluation for early or new onset type 1 diabetes mellitusOtelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are currently no approved treatments for this indication.Approved treatments for T1DM in the EU are insulins or insulin analogues.MedDRA version: 14.0Level: LLTClassification code 10012608Term: Diabetes mellitus insulin-dependentSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-002205-40-SETolerx, Inc.240
进行中（未招募）
不适用
Durable response therapy evaluation for early or new onset type 1 diabetes mellitusEUCTR2008-002205-40-DETolerx, Inc.240
进行中（未招募）
不适用
Durable response therapy evaluation for early or new onset type 1 diabetes mellitusEUCTR2008-002205-40-DKGlaxoSmithKline240
进行中（未招募）
1 期
Durable response therapy evaluation for early or new onset type 1 diabetes mellitusOtelixizumab is being developed for the treatment of patients with autoimmune T1DM with residual beta cell function (RBCF), with the goal of preserving RBCF in this patient population. There are currently no approved treatments for this indication. Approved treatments for T1DM in the EU are insulins or insulin analogues.MedDRA version: 14.0 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2008-002205-40-GBGlaxoSmithKline UK Limited